Search - tctmd.com

Displaying 241 - 260 of 547

Sort: Relevancy | Date

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

November 04, 2021

CVD Risk ‘Underappreciated’ After Adverse Pregnancy Outcomes

News Daily News

CVD Risk ‘Underappreciated’ After Adverse Pregnancy Outcomes

November 01, 2021

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

News Daily News

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

November 01, 2021

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

News Daily News

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

Michael O'Riordan

October 28, 2021

Starting DOACs Early After Ischemic Stroke Appears Safe

News Daily News

Starting DOACs Early After Ischemic Stroke Appears Safe

October 21, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Diabetes Progression in Statin-Treated Patients: VA Data

News Daily News

Diabetes Progression in Statin-Treated Patients: VA Data

Michael O'Riordan

October 06, 2021

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

News Daily News

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

Michael O'Riordan

October 04, 2021

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

News Daily News

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

Michael O'Riordan

October 01, 2021

Vasopressor/Steroid Combo Jump-starts Circulation for In-Hospital Cardiac Arrests

News Daily News

Vasopressor/Steroid Combo Jump-starts Circulation for In-Hospital Cardiac Arrests

September 30, 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

News Conference News HFSA 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

Michael O'Riordan

September 14, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

News Daily News

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

September 09, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.